<DOC>
	<DOC>NCT00121836</DOC>
	<brief_summary>This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus intravenous Avastin as first-line treatment in women with metastatic breast cancer. Patients received Xeloda 1000 mg/mÂ² orally (PO) twice daily (BID) on Days 1-15, and Avastin 15 mg intravenously (IV) on Day 1 of each 3-week cycle. The anticipated time on study treatment was until disease progression or unacceptable toxicity. The target sample size was &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Women &gt;=18 years of age HER2negative metastatic breast cancer Previous adjuvant chemotherapy or hormonal treatment &gt;=1 measurable target lesion Previous treatment with chemotherapy, an antiangiogenic agent, or a biologic therapy for advanced or metastatic cancer Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy Central nervous system metastases Other malignancy within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix Serious concurrent infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>